KR20220066116A - 재조합 인간 뉴레귤린 유도체 및 그의 용도 - Google Patents

재조합 인간 뉴레귤린 유도체 및 그의 용도 Download PDF

Info

Publication number
KR20220066116A
KR20220066116A KR1020227012793A KR20227012793A KR20220066116A KR 20220066116 A KR20220066116 A KR 20220066116A KR 1020227012793 A KR1020227012793 A KR 1020227012793A KR 20227012793 A KR20227012793 A KR 20227012793A KR 20220066116 A KR20220066116 A KR 20220066116A
Authority
KR
South Korea
Prior art keywords
nrg
amino acid
acid sequence
fusion polypeptide
neuregulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227012793A
Other languages
English (en)
Korean (ko)
Inventor
밍동 쪼우
Original Assignee
젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010955006.XA external-priority patent/CN112500493A/zh
Application filed by 젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드 filed Critical 젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드
Publication of KR20220066116A publication Critical patent/KR20220066116A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227012793A 2019-09-16 2020-09-14 재조합 인간 뉴레귤린 유도체 및 그의 용도 Pending KR20220066116A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910873003 2019-09-16
CN201910873003.9 2019-09-16
CN202010955006.X 2020-09-11
CN202010955006.XA CN112500493A (zh) 2019-09-16 2020-09-11 重组人神经调节蛋白衍生物及其用途
PCT/CN2020/114955 WO2021052277A1 (zh) 2019-09-16 2020-09-14 重组人神经调节蛋白衍生物及其用途

Publications (1)

Publication Number Publication Date
KR20220066116A true KR20220066116A (ko) 2022-05-23

Family

ID=74883174

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012793A Pending KR20220066116A (ko) 2019-09-16 2020-09-14 재조합 인간 뉴레귤린 유도체 및 그의 용도

Country Status (7)

Country Link
US (1) US20230057622A1 (https=)
EP (1) EP4032901A4 (https=)
JP (2) JP2022547335A (https=)
KR (1) KR20220066116A (https=)
AU (1) AU2020348436A1 (https=)
CA (1) CA3157354A1 (https=)
WO (1) WO2021052277A1 (https=)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AU745324B2 (en) 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20110166068A1 (en) * 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
GB201313235D0 (en) * 2013-07-24 2013-09-04 Univ Edinburgh Antiviral Compositions Methods and Animals
CN110946993A (zh) * 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) * 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP2020514370A (ja) * 2017-03-17 2020-05-21 キュアバック アーゲー 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤
CN108623672A (zh) * 2017-03-25 2018-10-09 成都贝爱特生物科技有限公司 新的egf-a和b的组合突变体制备及其在生物药物中的应用
AU2019209770B2 (en) * 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
FI3774859T3 (fi) * 2018-04-11 2024-05-24 Salubris Biotherapeutics Inc Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät

Also Published As

Publication number Publication date
WO2021052277A1 (zh) 2021-03-25
JP2025186253A (ja) 2025-12-23
AU2020348436A1 (en) 2022-04-07
CA3157354A1 (en) 2021-03-25
US20230057622A1 (en) 2023-02-23
EP4032901A1 (en) 2022-07-27
JP2022547335A (ja) 2022-11-11
EP4032901A4 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
CN102232084B (zh) 纽兰格林及其用途
US8158589B2 (en) Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
US9279012B2 (en) Method of reducing cell death by administering a nucleic acid encoding a paracrine factor of a mesenchymal stem cell
JP5701375B2 (ja) 血管新生促進用ペプチド及びその使用
JP2014001238A (ja) 細胞シグナル伝達タンパク質ｎｅｌｌ１を用いた、創傷治癒及び筋再生の促進方法
CN111629785A (zh) 促进缺血后细胞再生的系统和方法
JP5752782B2 (ja) 血管新生促進用ペプチド及びその使用
CN112585159B (zh) 神经调节蛋白多肽片段及其用途
US20060154333A1 (en) Pan-HER antagonists and methods of use
KR20220066116A (ko) 재조합 인간 뉴레귤린 유도체 및 그의 용도
US7534436B2 (en) Peptide fragments of the harp factor inhibiting angiogenesis
HK40081680A (en) Recombinant human neuregulin derivatives and use thereof
CN112500493A (zh) 重组人神经调节蛋白衍生物及其用途
KR20210116350A (ko) 심장줄기세포를 포함하는 허혈성 질환의 예방 또는 치료용 조성물
KR102801906B1 (ko) 피브릴린 재조합 단백질을 포함하는 줄기세포의 평활근세포로의 분화 촉진용 조성물
US7470769B2 (en) Epidermal growth factor receptor antagonists and methods of use
EP1911459A1 (en) Lymphangiogenesis promoter
KR20240155839A (ko) 심장줄기세포를 포함하는 허혈성 질환의 예방 또는 치료용 조성물
KR101595641B1 (ko) Cd31-itim 폴리펩타이드 또는 이를 코딩하는 유전자를 포함하는 혈관생성 촉진용 약학 조성물
CA2480423C (en) Truncated 24 kda basic fibroblast growth factor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000